Literature DB >> 16239233

Clinical trials in ovarian carcinoma: study methodology.

J B Vermorken1, M K B Parmar, M F Brady, E A Eisenhauer, T Hogberg, R F Ozols, J Rochon, G J S Rustin, S Sagae, R H M Verheijen.   

Abstract

Entities:  

Mesh：

Year:  2005        PMID： 16239233     DOI： 10.1093/annonc/mdi963

Source DB:  PubMed          Journal:  Ann Oncol        ISSN： 0923-7534            Impact factor:   32.976


× No keyword cloud information.
  5 in total

1.  Monitoring for lack of benefit: a critical component of a randomized clinical trial.

Authors:  Boris Freidlin; Edward L Korn
Journal:  J Clin Oncol       Date:  2008-12-08       Impact factor: 44.544

2.  Ovarian cancer clinical trial endpoints: Society of Gynecologic Oncology white paper.

Authors:  Thomas J Herzog; Deborah K Armstrong; Mark F Brady; Robert L Coleman; Mark H Einstein; Bradley J Monk; Robert S Mannel; J Tate Thigpen; Sharee A Umpierre; Jeannine A Villella; Ronald D Alvarez
Journal:  Gynecol Oncol       Date:  2013-11-15       Impact factor: 5.482

Review 3.  CA125-related tumor cell kinetics variables after chemotherapy in advanced ovarian cancer: a systematic review.

Authors:  G Colloca; A Venturino; I Governato
Journal:  Clin Transl Oncol       Date:  2015-11-06       Impact factor: 3.405

4.  Review of meta-analyses evaluating surrogate endpoints for overall survival in oncology.

Authors:  Beth Sherrill; James A Kaye; Rickard Sandin; Joseph C Cappelleri; Connie Chen
Journal:  Onco Targets Ther       Date:  2012-10-23       Impact factor: 4.147

Review 5.  Reporting of analyses from randomized controlled trials with multiple arms: a systematic review.

Authors:  Gabriel Baron; Elodie Perrodeau; Isabelle Boutron; Philippe Ravaud
Journal:  BMC Med       Date:  2013-03-27       Impact factor: 8.775
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.